Skip to main content
Premium Trial:

Request an Annual Quote

Congenica Strikes Asian Distribution Deal With Camtech Diagnostics

NEW YORK – Congenica said Tuesday that it has entered into a partnership with Camtech Diagnostics to market and distribute its software in Singapore, Malaysia, Japan and South Korea.

The deal marks a significant expansion in the Asia-Pacific region for Cambridge, UK-based Congenica. The company, which makes a modular and scalable data analytics tool for annotating and clinically interpreting genomic sequence data to support clinical decision-making, already has a presence in China by virtue of a partnership with Digital China Health Technologies of Hong Kong.

Camtech Diagnostics, a technology company with roots in microfluidics, will sell Congenica's flagship platform in the four countries, targeting laboratories and health systems that are applying genomics to rare diseases. Like Congenica, that company is headquartered in Cambridge, though it has operations in Singapore.

"The advanced healthcare systems of Asia-Pacific have been undergoing rapid development and growth. They have a clear need for fast, reliable tools to support the diagnosis of rare diseases," Camtech Managing Director Kuok Meng-Han said in a statement. "We are excited to partner with Congenica to roll out this platform and move closer to genomic medicine being more widely incorporated into standard clinical practice."

Congenica Chief Commercial Officer Muthu Meyyappan said that the distribution deal helps advance the company's stated goal of widening its global presence. "Camtech benefits from a strong reputation in Southeast Asia with an established network through which our platform can be rapidly distributed and integrated into rare disease diagnostic procedures," Meyyappan said.

Just last month, Congenica entered into a distribution agreement with Amplitech to distribute its products in France and other French-speaking European countries. 

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.